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previously irradiated surgery is not always feasible. The poor 
results obtained exclusive chemotherapy.We have the 
objective to study treatment outcome in these tumors 
recurrent head and neck, previously irradiated. 
 
Material and Methods: We evaluated 57 patients with 
recurrent disease, between 2005 to 2014.27 larynx, 6 
nasopharynx,12 oropharynx, 6 hypopharynx and 6 oral cavity. 
The initial dose received between 50 and 70 Gy, 25/57 
received radical radiotherapy,17 /57 radical chemoradiation; 
other adjuvant radiotherapy, of which 8 / 57 was combined 
with chemotherapy. In 24 / 57 nodal recurrence (N1-N2), 
local 18/57 (T2-T4),6/57 local+nodal recurrence, 9/57 
seconds tumor,. Reirradiation with external 3D 
conforma/IMRTl techniques/ and dose between 50 Gy and 70 
Gy. Time between initial treatment and relapse: 11 to 72 
months. 
 
Results: 39/57 cases were complete response, 8 / 57 partial 
response, 7/57 stabilization, 3/57 progresion. Late toxicity: 
xerostomia (G: 2 26/57, G: 3 4/57), moderate fibrosis (6 /57, 
one case trismus), 2 osteoradionecrosis fistula required 
surgical treatment. Local control: 80%, median survival one 
year and 50% 2 years free of disease, two died of distant 
metastasis greater than 35 months after second treatment. 
 
Conclusion: This type of treatment, once considered 
contraindicated, after analyzing various authors, the 
potential has not seen a high incidence of severe damage 
expected in healthy tissues. Aggressive treatment of this 
disease recurring, allowing long survival, even in extensive 
disease is superior to best supportive care. 
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Purpose or Objective: Head and neck squamous cell 
carcinoma (HNSCC) is the 6th most common cancer 
worldwide, and both the disease and its treatment are 
associated with high morbidity. FDG-PET CT imaging can be 
performed approximately 12 weeks following IMRT to exclude 
persistent disease at the primary tumour site and/or local 
neck nodes. This report considers how post-treatment PET CT 
scans may be utilised to inform the follow up of patients 
treated for HNSCC.  
 
Material and Methods: A retrospective review of HNSCC 
patients treated with IMRT with radical intent between 
December 2010 and February 2013 and who underwent a 
post-treatment PET CT scan. Overall, relapse-free and loco-
regional relapse-free survival calculated from date of biopsy 
to date of death, relapse or last follow up. PET CT reports 
were noted and categorised as follows: 
‘Low-risk’ - normal scan  
‘Intermediate-risk’ – showing post-treatment change or 
inflammation  
‘High-risk’ – in keeping with or highly suspicious of residual 
disease 
 
Results: 100 patients were identified. Median follow up was 
2.8 years (range 58 days to 3.9 years). On review of PET CT 
reports, 47 patients were categorised as low-risk, 27 as 
intermediate-risk and 26 as high-risk. 13 of the 26 high-risk 
patients underwent a subsequent biopsy, with residual 
disease in 3. 6 of the 27 intermediate-risk patients 
underwent biopsy, with residual disease in 1.  
3-year overall survival was 93.3% (95% C.I. 80.7 to 97.8%) for 
the low-risk group, 79.3% (95% C.I. 56.7 to 91.0%) for the 
intermediate-risk group and 38.8% (95% C.I. 18.3 to 58.9%) 
for the high-risk group [p <0.0001].  
3-year relapse-free survival was 78.5% (95% C.I. 60.1 to 
89.1%) for the low-risk group, 74.0% (95% C.I. 50.1 to 87.7%) 
for the intermediate-risk group and 33.9% (95% C.I. 15.3 to 
53.6%) for the high-risk group [p <0.0001].  
3-year loco-regional relapse-free survival was 91.4% (95% C.I. 
78.6 to 96.7%) for the low-risk group, 81.6% (95% C.I. 56.5 to 
93.0%) for the intermediate-risk group and 71.5% (95% C.I. 
49.1 to 85.3%) for the high-risk group [p = 0.0310, figure]  
 
 
 
Conclusion: This report confirms the value of the 12-week 
post-treatment PET CT scan in identifying the risk of loco-
regional relapse and death following IMRT treatment for 
HNSCC. This information could be used to identify patients in 
a good prognostic group who may benefit from entering 
follow-up protocols aimed at addressing psychosocial and 
survivorship issues, with high-risk patients undergoing more 
intensive follow-up aimed at detecting relapse of disease. 
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Purpose or Objective: FDG-PET is perceived as a valuable 
diagnostic tool for patients with cancer of unknown primary 
(CUP). In the literature, detection rates are approximately 
30% for pooled patient populations. Patients with isolated 
neck lymph nodes of squamous cell carcinoma, are usually 
examined by an ENT specialist with panendoscopy, sampling 
blind biopsies, CT or MRI of the neck, sometimes ultrasound 
of the neck and a chest CT. After these examinations have 
been performed without finding the primary cancer, FDG-PET 
detection rates are reported to be approximately 25%. For 
our head and neck cancer patient population with CUP 
intended for definitive radiochemotherapy, we hypothesize 
that the previously reported FDG-PET detection rates are too 
high. 
 
Material and Methods: In our hospital during 2007-2013, 361 
head and neck cancer patients had an FDG-PET-CT 
examination in fixation mask as part of the radiotherapy 
treatment planning. In this group, 31 patients had cervical 
lymph node metastases of squamous cell carcinoma of 
unknown origin. 
 
Results: Two (cancer of the vallecula and esophagus) of 
these 31 patients had their primary cancer detected by FDG-
PET-CT giving a detection rate of 6.5% (95% C.I.: 2%, 21%). 
 
Conclusion: The FDG-PET detection rate of the primary 
cancer for patients with cervical lymph node metastases of 
squamous cell carcinoma, who have been through the 
standard diagnostic work-up, is lower than previously 
reported. FDG-PET may be less useful for this purpose than 
what has been anticipated. 
 
